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Several disease-modifying therapies that appear to be more efﬁca-
cious than interferon beta 1b, which was the ﬁrst drug proven to be
effective in altering the natural history of the disease (The IFNBMultiple
Sclerosis Study Group, 1993; Karussis, 2013), have been recently pro-
posed for the treatment of relapsing–remitting multiple sclerosis
(MS). The so far approved disease-modifying drugs, although showing
variable efﬁcacy in reducing relapse risk and preserving neurological
7F. Serana et al. / Journal of Neuroimmunology 277 (2014) 6–12functions, differ in tolerability, likelihood of treatment adherence, risk of
major toxicity, and are associated to adverse effects of variable severity
(Wingerchuk and Carter, 2014).
Thus, the beneﬁt-to-risk ratio for each alternative treatmentmust be
carefully evaluated atmultiple levels when a therapeutic strategy has to
be chosen. Several factors should be taken into account for the prescrip-
tion of immunoactive drugs, such as severity and worsening of the dis-
ease, patient's concern about present or future symptoms and disability,
patient's tolerance to side effects, availability of other therapeutic
options, and existence of biomarkers identifying patients at higher risk
of developing severe adverse reactions. This is particularly urgent for
patients at risk to develop progressive multifocal leukoencephalopathy
(PML) because of natalizumab treatment. In fact, as of the 31st of May
2014, 474 cases of natalizumab-associated PML have been described
(http://multiple-sclerosisresearch.blogspot.it/2014/07/clinic-speak-
natalizumab-pml-update.html).
The present article reviews some biomarkers that have been
proposed to evaluate the safety of natalizumab therapy as well as the
most promising results in this ﬁeld.
2. Known predictive markers for natalizumab-related PML
PML is a demyelinating brain disease caused by the JC virus (JCV)
(Brew et al., 2010). JCV infection is frequently acquired during
childhood; afterwards, the virus persists in the body in a latent state,
replicating at low levels only episodically (Hou and Major, 2000;
Khalili et al., 2008). PML, which was initially diagnosed mainly in
patients with AIDS or lymphoproliferative disease (Calabrese et al.,
2007), is now also observed during therapy with a variety of
immunomodulating drugs, natalizumab being the most frequently im-
plicated, especially in patients without an underlying predisposing con-
dition (Carson et al., 2009; Schmedt et al., 2012; Piccinni et al., 2013). As
of September 2, 2014, the overall incidence of PML in natalizumab-
treated patients is 3.72 per 1000 patients (http://www.biogenidec-
international.com/tysabri.aspx?ID=4763; accessed October 24, 2014).
While in severely immunosuppressed patients PML is often fatal (Tan
andKoralnik, 2010), the disease developingunder natalizumab is not al-
ways lethal, with an overall mortality of 22% (http://www.biogenidec-
international.com/tysabri.aspx?ID=4763; accessed October 24, 2014),
mostly due to the PML immune reconstitution inﬂammatory syndrome
(Clifford et al., 2010). The majority of survivors of natalizumab-
associated PML are left with a moderate-to-severe disability, depending
on the location more than on the size of lesions, the most serious ones
being in the brainstem (Clifford et al., 2010).
In MS patients, an early diagnosis of PML in an asymptomatic phase
is crucial because it is associated with better clinical outcomes (Wattjes
et al., 2014); indeed, the sooner PML is recognized, the therapy stopped,
and plasma exchange initiated, the better the outcome (Chalkley and
Berger, 2013). However, at present, there is no blood biomarker of JCV
activity that can be used alone to diagnose PML, and a failure to detect
JCVDNA in the cerebrospinal ﬂuid (CSF) does not rule out the possibility
of having PML, particularly in the earlier stages of the disease (Brew
et al., 2010; Cordioli et al., 2014). The only humoral parameter obtained
routinely is the JCV seropositivity status,which is evaluated bydetecting
antibodies directed against JCVVP1 (themain surface JCV protein) using
the single validated STRATIFY JC virus™ assay (Gorelik et al., 2010; Bozic
et al., 2011; Lee et al., 2013).This assay allows neurologists to detect pa-
tients at higher risk of developing PML. In particular, three factors—the
presence of anti-JCV antibodies, with a lower risk of developing PML
in patients with low antibody titers (Plavina et al., 2014), previous use
of immunosuppressants, and protracted duration of treatment, espe-
cially if longer than 2 years—seem to contribute to the overall risk of
natalizumab-associated PML (Bloomgren et al., 2012). Patients with all
three risk factors are those at the greatest risk (Sandrock et al., 2011).
However, although this risk-factor algorithm may help identifying pa-
tients for whom natalizumab is appropriate and may reduce theincidence of PML, its use has some limitations. For instance, because
about 57.1% of MS patients are seropositive for JCV (a value very close
to the 60% observed in the general population), whereas PML is a rare
event, its usefulness in the stratiﬁcation of patients at risk of PML is lim-
ited (Bozic et al., 2011; Lee et al., 2013; Bozic et al., 2014). Furthermore,
it appears that the knowledge of these risk factors has not led to a reduc-
tion in the incidence of PML in natalizumab-treated patients. Indeed,
fromApril 2010 to February 2014 the incidence of PMLhas remained es-
sentially unchanged, regardless of natalizumab treatment duration
(Cutter and Stüve, 2014; Biogen Idec. https://medinfo.biogenidec.com).
The other strategies commonly used for the diagnosis of natalizumab-
induced PML, such as magnetic resonance imaging (MRI) (Vennegoor
et al., 2011; Ayzenberg et al., 2012), quantitative polymerase chain reac-
tion (PCR) for detection of JCV DNA in CSF (Kappos et al., 2011; Mentzer
et al., 2012; Berger et al., 2013), and JCV antibody index in CSF, which
measures intrathecal synthesis of anti-JCV antibodies (Warnke et al.,
2014), at present, do not appear to be useful as biomarkers predictive
of PML risk prior to therapy initiation.
3. Proposed alternative, immunological markers predictive of
natalizumab-related PML
Besides a reduced immune surveillance, other host immune
factors and modiﬁcations of immune-viral interplay may also play a
role in PML development. Viral mutations, facilitating the infection
of oligodendroglial cells, together with modiﬁcations of the immune
system composition, appear to be required for latent JCV to become
pathogenic (Weissert, 2011). Indeed, in natalizumab-treated pa-
tients, mutations in the coding regions of the viral capsid protein
VP1 and in the non-coding control region of the virus (Reid et al.,
2011) have been associated with PML. Furthermore, additional sec-
ondary effects of natalizumab on immune cells other than its ability
to inhibit the crossing of the blood brain barrier have also been doc-
umented (Stüve, 2008; Koudriavtseva et al., 2014). Thus, alternative
immunological markers helping in the identiﬁcation of MS patients
at risk of PML prior to initiation or during natalizumab therapy
could be critical in guiding the decision to start or cease treatment.
This review will focus on analysis performed on peripheral blood
samples, as reported below and in Table 1, because central nervous sys-
tem (CNS) tissue cannot be routinely obtained for diagnostic purposes
because of the potential adverse effects. Similarly, CSF, that may reﬂect
cellular events within the parenchyma, althoughmore easily accessible,
cannot be considered the ideal biological material for the screening of
natalizumab-treated patients at risk of PML.
3.1. Anti-JCV neutralizing activity
Very recently, a lack of a correlation between the level of anti-JCV an-
tibodies and anti-JCV neutralizing activity was demonstrated, suggest-
ing that the serum anti-JCV neutralizing activity could be better
correlated to the actual risk of developing PML during natalizumab
treatment (Diotti et al., 2014). This may possibly allow an improved
risk stratiﬁcation of natalizumab-treated patients.
3.2. Individual genetic predisposition
The risk of developing PML might critically depend on host genetic
factors that establish the immune response to the JCV, and protect
from its spread from the peripheral places of persistency or latency to
the brain. By determining HLA-alleles with single-nucleotide polymor-
phism imputation, PCR ampliﬁcation with sequence-speciﬁc primer
kits, or with a reverse PCR sequence-speciﬁc oligonucleotide method,
a strong association between class II gene variants and JCV infection
was found in Scandinavian and German patients with MS and in Swed-
ish controls (Sundqvist et al., 2014). In particular, alleles within the
HLA-DRB1*15 haplotype appear to be associatedwith a protective effect
Table 1
Proposed immunological biomarkers predicting PML.
Marker Method Clinical interpretation Reference
Presence of anti-JCV neutralizing anitbodies Neutralization assay on COS7 target cells Needs clinical validation in PML cases Diotti et al. (2014)
HLA-DRB1*15/HLA-DQB1*06:03 PCR with SSP, reverse PCR SSO and SNP
microarray
Associated respectively with decreased/
increased JVC carriage susceptibility
Sundqvist et al. (2014)
Decrease in iATP in CD4+ T cells Luciferase-activity based assay Associated with PMLa, non-predictive Haghikia et al. (2011);
Goelz et al. (2011)
Increase of IL-10 production by CD4+ T cells IL-10+ cells quantiﬁcation by ﬂow cytomerty
after antigenic stimulation in vitro
Associated with PML Perkins et al. (2012)
Increased miRNA-320 and miRNA-320b plus
decreased miRNA-629 expression
Quantitative real time RT-PCR Associated with PML Muñoz-Culla et al.
(2014)
Reduced CD62L-expressing CD4+ T cells Flow cytometry Predictive of PMLb Schwab et al. (2013)
Reduced CD62L-expressing CD4+ T cells plus
anti-JCV antibody index positivity
Flow cytometry and ELISA Predictive of PML Schwab et al. (2014)
Decreased CD11a expression on CD4+ and
CD8+ T cells
Flow cytometry Predictive of PML, low sensitivity Jilek et al. (2014);
Schwab et al. (2013)
Decreased TRECs and increased KRECs
quantiﬁcation
Quantitative real time PCR Predictive of PML Sottini et al. (2012)
Reduced TCR repertoire diversity CDR3 spectratyping Predictive of PML Sottini et al. (2012)
SNP: single-nucleotide polymorphism; SSP: sequence-speciﬁc primers; SSO: sequence speciﬁc oligonucleotide; and CDR3: complementarity determining region 3.
a Associated with PML: cross-sectional evidence only; still needs to be validated in longitudinal studies comparing pre vs. post PML samples.
b Predictive of PML: longitudinal studies comparing pre vs. post PML samples.
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an opposite association. The authors suggest that CD4+ T cells, restrict-
ed by class II molecules, are crucial for the host control of JCV infection.
This is of relevance, but it is necessary to remember that the DRB1*15-
DQA1*01:02-DQB1*06:02-haplotype is the most strongly associated
MS genetic risk factor; therefore, based only on this feature, themajority
of patients would turn out as good candidates for natalizumab. Howev-
er, because theHLA-DRB1*15:01 haplotypewas also associated to lower
antibody levels, which, in turn, have been associated to a lower PML risk
(Plavina et al., 2014), the testmay be useful to identify—among all those
who are anti-JCV seropositive—that smaller fraction of patients lacking
the genetic feature who should be at increased risk, and, therefore,
would deserve a closermonitoring. If future studieswill yield additional
evidences directly linking these haplotypes to PML incidence, the
knowledge of the host genetic factors inﬂuencing the response to JCV
might become of great help in identifying patients at a low risk of
PML. This information could be easily obtained, considering that, with
the advent of high-throughput genetic screening approaches, genetic
data are being acquired in shorter times and at decreasing costs
(Erlich, 2012).3.3. Bioenergetic values in immune cells
JCV infection control involves the recognition of viral antigens by
CD4+ lymphocytes carrying the “appropriate”HLA-class II molecules
(Sundqvist et al., 2014), and the subsequent activation of cytotoxic
CD8+ T cells. These activities are accompanied by phenotypic and
functional modiﬁcations that require an enhanced supply of ATP-
generating metabolites to meet the increased bioenergetic demands
(Fox et al., 2005). Intracellular CD4+-ATP concentration (iATP) in
phytohaemagglutinin-stimulated CD4+ T cells of 16 patients with
monoclonal antibodies-associated PML, including 8 treated with
natalizumab, was reduced by 59% in comparison to healthy controls,
with 14 patients with iATP levels at/or below 3rd percentile of
healthy control values (Haghikia et al., 2011). While the authors of
the study proposed that the measure of decreased iATP may assist
in risk stratiﬁcation and monitoring of patients under monoclonal
antibody immunotherapy, this hypothesis is in conﬂict with other
data demonstrating that patients who subsequently developed PML
had iATP levels in the normal range and not differing from those of
patients without PML (Goelz et al., 2011).3.4. IL-10 production by CD4+ T cells
Some studies investigated whether JCV-speciﬁc T-cell responses in
healthy donors and natalizumab-treatedMSpatients showed functional
differences that could account for the development of natalizumab-
associated PML. The measure of JCV-speciﬁc T-cell responses directed
against the JCV VP1 protein by quantiﬁcation of interferon gamma
production yielded conﬂicting results when examining longitudinal
T-cell responses to JCV in individuals withMS treatedwith natalizumab
(Chen et al., 2009; Jilek et al., 2010). Peripheral bloodmononuclear cells
of PML patients, when stimulated by anti-CD28 and anti-CD49d mo-
noclonal antibodies, in the presence or absence of the Staphylococcus
aureus enterotoxin B superantigen, did not show detectable T-cell
responses to JCV, or had JCV-speciﬁc CD4+ T-cell responses uniquely
dominated by IL-10 production rather than interferon gamma
(Perkins et al., 2012). Thus, because the production of IL-10 by JCV-
speciﬁc CD4+ T cells may interfere with this antiviral activity to the
detriment of JCV replication control, either locally in the CNS or in pe-
ripheral tissues, becoming causative of PML, the authors proposed the
measure of IL-10 for the identiﬁcation of patient prone to develop
PML. Against this possibility are the ﬁndings that IL-10 production
was not detected earlier than 4 months after the clinical onset of PML
and that increased JCV-speciﬁc IL-10 production by peripheral blood
mononuclear cells can be observed in HIV+ subjects with PML, but not
in non-HIV PML cases (Weber et al., 2001).
3.5. Blood microRNA expression pattern
It has been recently demonstrated that natalizumab alters
microRNA (miRNA) expression in B cells of MS patients (Sievers
et al., 2012), and that expression levels of three miRNAs, namely
let-7c, miR-125a-5p and miR-642, were modiﬁed after 6 months of
therapy. Furthermore, the three miRNAs, miR-320, miR-320b and
miR-629, which are differentially expressed in the PML and non-
PML groups after 12 months of treatment, have been proposed as
possible biomarkers for individual PML risk assessment (Muñoz-
Culla et al., 2014). Although the lack of a longitudinal study on sam-
ples obtained before PML onset limits the signiﬁcance of this study,
these data could be of particular interest because more than one da-
tabase predicts that miR-320 and miR-320b have putative binding
sites in L-selectin, which probably is, at the present, one of the
most promising immunological biomarker of PML development.
9F. Serana et al. / Journal of Neuroimmunology 277 (2014) 6–123.6. L-selectin (CD62L) percentage on CD4+ T cells
L-selectin, which acts as a “homing receptor” for lymphocytes to
enter secondary lymphoid tissues via high endothelial venules, was
evaluated in a study that included 289 subjects with MS; 224 patients
had been treated for 18–80 months with natalizumab, 21 had received
glatiramer acetate or interferon beta, 28 were untreated MS subjects
and 16 were natalizumab-treated patients that developed PML
(Schwab et al., 2013). In eight of them, blood samples were available
also prior to the diagnosis of PML and in three before natalizumab ther-
apy initiation. In comparison with MS patients receiving glatiramer ac-
etate or interferon beta and with healthy controls, patients long-term
treated with natalizumab had a percentage of CD4+ T cells expressing
L-selectin that was under the cut-off (established by subtracting 2 SD
from the mean of the control cohort). The presence of a very low per-
centage of these cells was highly correlated with the risk of developing
PML in the groupwith available pre-PML samples when comparedwith
non-PML natalizumab-treated patients. These data demonstrated that
the cell-based assessment of the percentage of L-selectin-expressing
CD4+ T cells has the possibility of providing a biomarker for an individ-
ualized natalizumab-related PML risk assessment, and perhaps also for
HIV-associated PML risks (Schwab et al., 2013; Schneider-Hohendorf
et al., 2014).
It has been calculated that the detection of anti-JCV antibodies alone
determined 54.2% of the study cohort patients to be at risk of PML,while
CD62L set the proportional risk at 6.6%. A combination of the two pa-
rameters reduced the risk percentage to 4.4% (Schwab et al., 2014).
However, because a natalizumab-treated population usually has a risk
of about 1 out of 300, probablymost of these patientswill never develop
PML.
Themajor problemof L-selectin detection is related to the highly un-
stable ex-vivo expression of this molecule on the cell surface and to the
difﬁculties in the standardization of staining protocols before ﬂow
cytometry analysis. Therefore, a rigorous setup of the technique and
the use of a large number of controls would be recommended.
A sustained decrease of adhesion molecules involved in the leuko-
cyte trafﬁcking, alpha-4 and beta-1 integrin surface level in particular,
was observed in T cells, B cells, natural killer cells, natural killer T cells,
and dendritic cells (Wipﬂer et al., 2011; de Andrés et al., 2012; Harrer
et al., 2012), but only CD11a expression after 2 years of natalizumab
treatment, when PML incidence reaches its peak level, has been pro-
posed as a PML biomarker (Jilek et al., 2014).
3.7. Newly produced T and B lymphocytes and T-cell repertoire diversity
It has been recently demonstrated that CD34+ progenitor cells,
which may harbor JCV, are mobilized at high concentrations from
bone marrow into the peripheral circulation by natalizumab
(Zohren et al., 2008). A portion of these latently infected cells ini-
tiates its differentiation into CD19+ B lymphocytes, which can
harbor the virus as well (Frohman et al., 2014). Starting from these
ﬁndings, we investigated whether the drug also increases the release
of newly produced T and B lymphocytes from thymus and bone
marrow; to this end, we quantiﬁed T-cell receptor excision circles
(TRECs) and K-deleting recombination excision circles (KRECs),
which have been described as markers of new T- and B-cell release
from their production sites (Sottini et al., 2010). We found that
both TRECs and KRECs signiﬁcantly increased in natalizumab-
treated patients (Zanotti et al., 2012), excluding one patient who
developed PML after 34 months of therapy. In this patient, on the
contrary, who showed a very low number of TRECs+ cells already
before therapy initiation, natalizumab was not capable of increasing
the thymic release of newly produced T lymphocytes at any time of
the analysis, which was performed in samples obtained at 6, 12, 15
and 34 months of therapy. This reduced thymic output was con-
ﬁrmed by quantifying CD4+CD45RA+CCR7+CD31+ recent Temigrants by ﬂow cytometry. In contrast, in the same patient,
KRECs, which were also very low before the ﬁrst natalizumab infu-
sion, initially increased to reach the values observed in the other
natalizumab-treated patients, but then decreased at the time of
PML onset (Sottini et al., 2012).
A low level of TRECs, such as that found in untreated MS patients
(Chiarini et al., 2010), can be one of the reasons for the limited T-cell re-
ceptor diversity commonly found in MS patients, who show several
T-cell receptor V beta family (TCRBV) clonal expansions, some of
which long-lasting, in the blood, CSF or in brain lesions (Gran et al.,
1998; Muraro et al., 2006; Junker et al., 2007). On the other hand, be-
cause of the increased thymic output associated to natalizumab therapy
(Zanotti et al., 2012), one could expect a relative enlargement of T-cell
diversity. This possibility has been tested by studying the TCRBV reper-
toire with a method called complementarity-determining region-3
(CDR3) spectratyping, which analyses the length distribution of the
CDR3 regions of TCRBV families. In young healthy subjects, the distribu-
tion of CDR3 lengths in the various TCRBV families is “normal” or
Gaussian-like (Zou et al., 2014) and is constant during time (Fig. 1A).
Deviations from the Gaussian-like distribution in the spectratype pro-
ﬁles are indicative of either disappearance or expansion of individual
T-cell clones. According to the initial hypothesis, the peripheral T-cell
repertoire restrictions found in blood of MS patients appeared less
prominent during therapy with natalizumab (Zanotti et al., 2012;
Warnke et al., 2013), whereas, after natalizumab therapy discon-
tinuation, this enlargement of the T-cell repertoire diversity promptly
disappeared (Chiarini et al., in press). On the contrary, in the patient
that developed PML after 34 months of therapy with natalizumab,
who showed persistently low TREC levels in the presence of a normal
number of KRECs, we found profound alterations in the TCRBV
spectratype proﬁles. Deviations from the Gaussian-like distribution,
presence of 1 or 2 dominant peaks, and absence of detectable peaks
were observed in samples obtained before natalizumab therapy ini-
tiation, at 12 months of treatment and then at the moment of PML
development (Fig. 1B) (Sottini et al., 2012). Therefore, we propose
that in the presence of a long lasting decrease of TRECs and of re-
stricted T-cell repertoires, occurring when the levels of KRECs in-
crease, a natalizumab-treated patient could be considered at risk of
PML.
In support of this hypothesis, it should be also taken into account
that JCV mutations have been associated to PML in natalizumab-
treated patients (Reid et al., 2011). In this context, a long lasting de-
crease of the thymic output, on one hand, depletes the peripheral
T-cell compartment of the repertoire diversity necessary for an effective
antigen recognition; on the other hand it increases repertoire restric-
tions in the CSF (Warnke et al., 2013). This would likely cause an im-
paired identiﬁcation of JCV displaying mutated antigens carried by
CD34+ progenitor cells and B lymphocytes mobilized by natalizumab
(Zohren et al., 2008; Frohman et al., 2014).
Therefore, a quantiﬁcation of TRECs and KRECs can be a potential
tool to identify patients at risk of developing PML, but only if performed
in longitudinal samples. Based on this and on previously published lon-
gitudinal studies, an updated, tentative risk-stratiﬁcation algorithm
would be to perform TREC andKREC quantiﬁcation to followup patients
who can be considered at an intermediate risk, for example patients
bearing only one of two well-consolidated highest-risk features, i.e. an-
tibody positivity without a treatment duration longer than 24 months
(Bloomgren et al., 2012), in particular if they also have lymphocytes
with a low level of CD62L expression (Suppl. Fig. 1). This could be
more feasibly done by setting-up an easierway of TREC andKRECdetec-
tion, as that proposed for newborn screening (Borte et al., 2012). On the
contrary, the currently available techniques for the analysis of T-cell di-
versity (Bolotin et al., 2012; Zanotti et al., 2012; Warnke et al., 2013),
due to complexity and costs, cannot be used as a screening of patients
at risk of PML, but can be a useful tool to conﬁrm the immune defects
caused by a long lasting decrease of TRECs.
T0
T34
TCRBV FAMILIES
181792 4 15 21 2416 2214 253 208 11 12 23 6 75 131 
T12
Ctrl T0
Ctrl T12
181792 4 21 2416 2214 253 208 11 12 23 6 75 131 15
B
A
Fig. 1.Analysis of T-cell diversity. CDR3 size spectratypingmeasures CDR3 region length variationswithin each TCRBVgene family ampliﬁed bymultiplex PCR (Zanotti et al., 2012;Warnke
et al., 2013). (A) In a representative age-matched healthy control (Ctrl), because of the random generation of a very large number of T-cell receptors with unique CDR3 regions, the
spectratype peaks of CDR3 region lengths follow, for the most part, bell-shaped curves with more than 7 peaks, corresponding to a Gaussian-like distribution, with only few peaks not
ﬁtting the normal distribution. The spectratyping of the same subject after 1 year (T12) is unchanged. (B) In an MS patient that developed PML after 34 months of natalizumab therapy,
alterations of CDR3 proﬁles over time, including deviation from Gaussian-like distribution, presence of 1 or 2 dominant peaks, and lack of expected peaks (less than 7 peaks), were ob-
served in several TCRBV families ampliﬁed starting from samples obtained before natalizumab therapy initiation (T0) and at 12 (T12) and 34 (T34) months of therapy.
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In the last few years, several studies evaluating speciﬁc biomarkers
for MS patients under natalizumab therapy have been carried out and
their results show some potential to improve the safety and efﬁcacy of
the therapy. However, most of these studies included only a small num-
ber of patients, and therefore, no deﬁnitive conclusions can be drawn as
to which are the most appropriate biomarkers to prevent PML onset.
Furthermore, the complexity of the techniques used for identiﬁcation
of these biomarkers and the lack of method standardization currently
limit their routine application. Consequently, any proposed, novel
marker would require validation in multicenter clinical trials. Based on
the available evidence indicating that PML risk markedly increases
after 24 months of natalizumab treatment (Bloomgren et al., 2012), lon-
gitudinal studies of at least 36–48 months would be recommended to
correctly deﬁne which markers have enough sensitivity in detecting
the disease before its onset. The ﬁnal scope would be to develop assays
that may advise more rational therapy switches before reaching the
high risk zone of 24 months of treatment.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jneuroim.2014.10.011.References
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